Biotech and Pharmaceuticals Medicine

More

  • Cougar

    This fall ABC is launching a new show with Courtney Cox called "Cougar Town." Courtney was one of my favorite "Friends" stars and cougars are certainly a hot cultural phenomenon. Could cougars be five minutes ago by the time the show premieres? Perhaps. But maybe ABC has a hit on its hands. New TV shows are always a roll of the dice. And so is Johnson & Johnson's journey into "Cougar Town."

  • Amylin

    It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.

  • GW Pharmaceuticals

    I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.

  • cadeuses2.jpg

    Cracking down on medical industry payments to doctors, the Vermont legislature has passed a law requiring drug and device makers to publicly disclose all money given to physicians and other health care providers, naming names and listing dollar amounts, the New York Times reports.

  • Medtronic

    Medtronic may have set a record. The world's biggest medical device maker put out six press releases this morning.

  • Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.

  • boston_scientific.jpg

    This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.

  • Pfizer

    Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.

  • Novartis Headquarters

    What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.

  • Carl Icahn

    Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.

  • doctor

    As walk-in clinics at stores like CVS and Wal-Mart offer convenient alternatives to doctors’ offices and hospital emergency rooms, some hospitals are fighting back - with walk-in clinics at some of those same retailers.

  • Amylin

    Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.

  • GlaxoSmithKline

    The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.

  • A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.

  • Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.

  • Surgeons

    The Obama administration plans to spend $1.1 billion over the next few years on comparative studies to determine the effectiveness of competing treatments for common conditions like back pain, heart disease and prostate cancer.

  • Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.

  • It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.

  • Amylin

    You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.

  • Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.